The success of immunotherapy in neoadjuvant and adjuvant settings has rendered the traditional, sequential referral model (dermatologist to surgeon to oncologist) obsolete. Optimal care now demands an integrated, team-based discussion among all specialists *before* the first treatment decision is made to determine the best sequence and timing.

ITP caused by immune checkpoint inhibitors (ICIs) is rare (0.25% incidence) but generally has a good prognosis. Most patients respond to standard first-line ITP therapies, and approximately 70% of those re-challenged with the ICI can continue treatment without a recurrence of ITP.

T-cells have natural inhibitory signals, or "brakes" (like PD-1), to prevent over-activation. Some cancers exploit this. Checkpoint inhibitor drugs block these brakes, unleashing a patient's existing T-cells to attack cancer cells more aggressively. This approach has been miraculous for cancers like melanoma.

The primary goal after managing immune checkpoint inhibitor (ICI)-induced ITP is resuming cancer therapy. Data shows most patients do not experience a relapse of ITP upon re-challenge with the ICI, allowing them to continue their effective cancer treatment.

T-cell engagers (TCEs) are likely to be safer in autoimmune conditions than in cancer. Autoimmune patients have a relatively normal B-cell count, unlike the massive proliferation in hematologic cancers. This lower target cell burden naturally limits the scale of T-cell activation and inflammatory toxicity.

Successful immunotherapies like anti-PD-1 work by shifting the battlefield's arithmetic. They enhance the efficiency of each T-cell, allowing one cell to destroy five or ten cancer cells instead of three. This turns the fight into a 'numbers game' that the immune system can finally win.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

A PD-L1 CPS score of zero should not automatically disqualify patients with metastatic anal cancer from receiving immunotherapy. The clinical distinction between a CPS of zero and one is marginal, and given the therapy's potential for benefit and low toxicity, clinicians should give patients the benefit of the doubt and offer the treatment.

While immunotherapy was a massive leap forward, Dr. Saav Solanki states the next innovation frontier is combining it with newer modalities. Antibody-drug conjugates (ADCs) and T-cell engagers are being used to recruit the immune system into the tumor microenvironment, helping patients who don't respond to current immunotherapies.